Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) (TB-PRACTECAL)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02589782 |
|
Recruitment Status : Unknown
Verified May 2021 by Medecins Sans Frontieres, Netherlands.
Recruitment status was: Active, not recruiting
First Posted : October 28, 2015
Last Update Posted : May 14, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Tuberculosis, Multidrug-Resistant Extensively Drug-Resistant Tuberculosis Tuberculosis, Pulmonary | Drug: Bedaquiline Drug: Pretomanid Drug: Moxifloxacin Drug: Linezolid Drug: Clofazimine Drug: Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB. | Phase 2 Phase 3 |
This is a multi-centre, open label, multi-arm, randomised, controlled, phase II-III trial; evaluating short treatment regimens containing bedaquiline and pretomanid in combination with existing and re-purposed anti-TB drugs for the treatment of biologically confirmed pulmonary multidrug-resistant TB (MDR-TB).
The study will be divided into two stages, with a seamless transition between the stages, meaning recruitment into an arm will only stop after a decision has been taken following stage 1 primary end point data analysis. All recruited patients will be followed up to 108 weeks post randomisation unless they die or withdraw consent. The local standard of care (SOC) MDR-TB regimen will be used as the internal control for both safety and efficacy.
The first stage corresponds to a Phase II trial of safety and preliminary efficacy in patients with MDR-TB. Patients will be recruited into 3 parallel B and Pa containing regimen arms plus a SOC control. The main objective of Stage 1 is to select drug regimens for evaluation in Stage 2 based on 8 week safety and efficacy endpoints. All stage 1 patients will be hospitalised for 8 weeks for intensive cardiological evaluations to establish the QT-specific liability of the regimens.
Investigational arms that do not meet predefined safety and efficacy criteria (percentage culture conversion >40%; percentage discontinuation and death <45%) will not be considered for further evaluation. The regimens that do not meet these pre-defined safety and/or efficacy criteria will be eligible to be evaluated for long term safety, tolerability and efficacy in Stage 2.
If less than two investigational arms are available for stage two assessment, the SAC will make recommendations on whether new arms should be introduced in the study. If more than two arms are available for the Stage 2 assessment, two regimens will be chosen. The SAC will make recommendations on which arms to take forward to the trial steering committee.
The second stage corresponds to a phase III trial. Patients in this stage will be recruited into the arms chosen from stage 1 plus the SOC. The regimens will primarily be evaluated for safety and efficacy in comparison with the SOC arm at 72 weeks post randomisation. The primary efficacy outcome will be a composite endpoint of the percentage of unfavourable outcomes. The secondary outcomes will include safety outcomes and in particular the percentage of Grade 3 or 4 AEs and SAEs in the investigational regimens compared with the SOC.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 552 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomised, Controlled, Open-Label, Phase II-III Trial to Evaluate the Safety and Efficacy of Regimens Containing Bedaquiline and Pretomanid for the Treatment of Adult Patients With Pulmonary Multidrug Resistant Tuberculosis |
| Actual Study Start Date : | January 2017 |
| Estimated Primary Completion Date : | September 2022 |
| Estimated Study Completion Date : | December 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Regimen 1
Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated
|
Drug: Bedaquiline
Other Names:
Drug: Pretomanid Other Name: PA-824 Drug: Moxifloxacin Other Name: Avelox Drug: Linezolid Other Name: Zyvox |
|
Experimental: Regimen 2
Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks
|
Drug: Bedaquiline
Other Names:
Drug: Pretomanid Other Name: PA-824 Drug: Linezolid Other Name: Zyvox Drug: Clofazimine Other Name: Lamprene |
|
Experimental: Regimen 3
Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)
|
Drug: Bedaquiline
Other Names:
Drug: Pretomanid Other Name: PA-824 Drug: Linezolid Other Name: Zyvox |
|
Active Comparator: Control Regimen
Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
|
Drug: Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB. |
- Stage 1:Percentage of patients with culture conversion in liquid media at 8 weeks post randomisation. [ Time Frame: 8 weeks post randomisation ]
- Stage 1: Percentage of patients who discontinue treatment for any reason or die [ Time Frame: 8 weeks post randomisation ]
- Stage 2: Percentage of patients with an unfavourable outcome (failure, death, recurrence, loss to follow-up) [ Time Frame: 72 weeks post-randomisation ]
- Stage 1: Percentage of patients with grade 3 or higher QT prolongation [ Time Frame: within 8 weeks post randomisation ]
- Stage 1: Percentage of patients experiencing at least one Serious Adverse Event (SAE) [ Time Frame: within 8 weeks post randomisation ]
- Stage 1:Percentage of patients experiencing at least one new grade 3 or higher Adverse Event [ Time Frame: within 8 weeks post randomisation ]
- Stage 2: Percentage of patients with culture conversion [ Time Frame: 12 weeks post randomisation ]
- Stage 2: Percentage of patients with an unfavourable outcome (i.e. failure, treatment discontinuation, death, loss to follow up) [ Time Frame: 24 weeks post randomisation ]
- Stage 2: Percentage of patients with an unfavourable outcome (i.e. failure, treatment discontinuation, death, loss to follow up, still on treatment at censure and recurrence) [ Time Frame: 108 weeks post randomisation ]
- Stage 2: Median time to culture conversion [ Time Frame: 108 weeks ]
- Stage 2: Percentage of patients with an SAE or new grade 3 or higher AE [ Time Frame: 72 weeks post randomisation ]
- Stage 2: Percentage of patients with an SAE or new grade 3 or higher AE [ Time Frame: 108 weeks post randomisation ]
- Stage 2: Percentage of patients with an SAE or new grade 3 or higher AE at the end of treatment [ Time Frame: 24 weeks in investigational arms and 108 weeks in SOC arm ]The percentage of patients with an SAE or new grade 3 or higher AE at the end of treatment in the investigational arms (maximum of 24 weeks) and the SOC arm which varies in length (maximum 108 weeks).
- Stage 2: Mean single ΔQTcF [ Time Frame: 24 weeks post randomisation ]
- Stage 2: Percentage of patients experiencing recurrence [ Time Frame: week 48 in investigational arms ]
- Stage 2: Plasma drug concentrations [ Time Frame: In relation to dose intake and start of treatment over a 72 week period ]
- Stage 2: TB drug hair levels [ Time Frame: In relation to dose intake and start of treatment over a 72 week period ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 15 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion criteria:
Patients eligible for inclusion in the trial must fulfil all of the following criteria:
- Male or female subjects aged 15 years of age or above, regardless of HIV status;
- Microbiological test (molecular or phenotypic) confirming presence of M. tuberculosis;
- Resistant to at least rifampicin by either molecular or phenotypic drug susceptibility test;
- Completed informed consent form (ICF);
Exclusion criteria:
Patients will not be eligible for inclusion in the trial if they meet any of the following criteria:
- Known allergies, hypersensitivity, or intolerance to any of the study drugs;
- Pregnant or breast-feeding; or unwilling to use appropriate contraceptive measures
- Liver enzymes >3 times the upper limit of normal (AST or ALT);
- Any condition (social or medical) which, in the opinion of the investigator, would make study participation unsafe;
- Taking any medications contraindicated with the medicines in the trial;
- QTcF > 450ms;
- One or more risk factors for QT prolongation (excluding age and gender) or other uncorrected risk factors for TdP;
- History of cardiac disease, syncopal episodes, symptomatic or asymptomatic arrhythmias (with the exception of sinus arrhythmia);
- Any baseline biochemical laboratory value consistent with Grade 4 toxicity.
- Moribund
- Known resistance to bedaquiline, pretomanid, delamanid or linezolid.
- Prior use of bedaquiline and/or pretomanid and/or linezolid and/or delamanid for one or more months.
-
Patients not eligible to start a new course of MDR-TB/XDR-TB treatment according to local protocol, including but not limited to:
- currently on MDR-TB treatment for more than 2 weeks (and not failing)
- unstable address
- loss to follow-up in previous treatment with no change in circumstance and motivation.
- Tuberculous meningoencephalitis, brain abscesses, osteomyelitis or arthritis.
PKPD inclusion/exclusion:
- Adult patients (aged 18 years or above) recruited into the investigational arms of the TB-PRACTECAL trial in the approved sites.
- Willing to sign the sub-study informed consent form after agreeing to the additional blood draws.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02589782
| Belarus | |
| Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital | |
| Minsk, Belarus | |
| South Africa | |
| Helen Jospeh Hospital | |
| Johannesburg, Gauteng, South Africa, 2092 | |
| Doris Goodwin Hospital | |
| Pietermaritzburg, KwaZulu Natal, South Africa | |
| THINK Clinical Trial Unit, Hillcrest | |
| Durban, KwaZulu-Natal, South Africa, 3650 | |
| King DinuZulu Hospital | |
| Durban, KwaZulu-Natal, South Africa, 4091 | |
| Uzbekistan | |
| Republican TB Hospital No. 2 | |
| Nukus, Karakalpakstan, Uzbekistan | |
| Sh Alimov Republican Specialised Scientific-Practical Medical Centre for Phthysiology and Pulmonology Hospital | |
| Tashkent, Uzbekistan | |
| Principal Investigator: | Bern-Thomas Nyang'wa, MD | Medecins Sans Frontieres, Netherlands |
| Responsible Party: | Medecins Sans Frontieres, Netherlands |
| ClinicalTrials.gov Identifier: | NCT02589782 |
| Other Study ID Numbers: |
1541 |
| First Posted: | October 28, 2015 Key Record Dates |
| Last Update Posted: | May 14, 2021 |
| Last Verified: | May 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
|
bedaquiline Nitroimidazoles diarylquinolines linezolid |
clofazimine pretomanid moxifloxacin |
|
Tuberculosis Tuberculosis, Multidrug-Resistant Tuberculosis, Pulmonary Extensively Drug-Resistant Tuberculosis Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections Bacterial Infections and Mycoses Infections Respiratory Tract Infections Lung Diseases Respiratory Tract Diseases Moxifloxacin |
Linezolid Bedaquiline Clofazimine Anti-Bacterial Agents Anti-Infective Agents Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Protein Synthesis Inhibitors Antitubercular Agents Anti-Inflammatory Agents Leprostatic Agents |